Enantia has been awarded the "Premi Senén Vilaró 2011" as the best innovatory company that has spun off from an academic group from the University of Barcelona. “Bosch i Gimpera Foundation” gives this prize to Enantia as a recognition of Enantia’s track record in reverting its scientific and technical knowledge to the society. “Bosch i Gimpera Foundation” acts as a bridge between University of Barcelona and companies, promoting R&D cooperation between public and private sectors. For more information follow the link www.fbg.ub.edu/index.php

 (Nov 28th, 2011)

Once more, we were delighted to meet our clients and partners and those companies we had the opportunity to meet for the first time, during the thrilling CPhI 2011. We hope to see you all again at CPhI 2012 edition in Madrid.

(Nov 10th, 2011) 

On February 7th, 2011, Mr. Ángel Gabilondo, Minister of Education of the Spanish Government, visited Enantia at its premises in the Barcelona Science Park. He was accompanied by Mr. Fernando Albericio (Director of the Barcelona Science Park), Mr. Joaquim Coello (President of the UB Social Council), Mr. Dídac Ramírez (UB Rector) and Mr. Antoni Castellà (Secretary, University and Research, Generalitat de Catalunya).

Enantia's CEO Mr. Llorenç Rafecas (left in the picture) is explaining to the minister how the company evolved since its foundation as a spin-off of the University of Barcelona back in 2003 to a well known and respected technology provider not only in Spain but also in Europe and the United States. With a staff of more than 40, Enantia has established itself as a leader in the field of chiral synthesis and crystal engineering, developing its own projects and offering services to the pharma, fine chemical and biotech sectors.

(February 16th, 2011)

Enantia will be present at the upcoming 2011 informEx edition to be held next February 7-10 in Charlotte, NC (booth#2165). We kindly invite to visit our booth to all visitors interested in learning about our latest technologies on crystalline forms (co-crystals and polymorphs), catalysts for enantioselective hydrogenation reactions and asymmetric synthesis expertise.

(Feb 2nd, 2011)

Once again Enantia was present in a new thrilling edition of CPhI. We want to kindly thank the many visitors that approached our stand interested to know more of Enantia. See you all in the next CPhI event to be held in Frankfurt in 2011.

(Dec 16th, 2010)

Enantia was exhibiting in BioSpain 2010, the consolidated event for the Spanish biotech sector. We want to thank to all those that shared interesting and fruitful meetings with us.

(Dec 16th, 2010)

Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the NEOGENIUS project will run for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.

Enantia has been selected as custom synthesis provider to support the drug discovery activities of the consortium.

The history of NEOGENIUS as a consortium can be traced back to the GENIUS PHARMA project, a CENIT project approved in the first call for this programme in 2006 in which, in adition to Almirall, Esteve and Palau Pharma, other technological companies, among them, Enantia, also participated. GENIUS PHARMA attained its objective of consolidating different SMEs and PROs in Spain as technological platforms in different pharmaceutical research settings. In fact, NEOGENIUS’s external collaborations have been established with platforms from GENIUS PHARMA, which will provide this process with a high degree of inter-regionality and multidisciplinarity.

(May 18th, 2010)

From March 8^th to 10^th Enantia will be attending BIO-Europe Spring 2010 in Barcelona. This partnering venue is ideal for interaction between the different players involved in the drug discovery arena. Therefore, we kindly invite all the participants to meet us there to discuss how we can contribute to their projects.

(Mar 5, 2010)

Effective December 23^rd, 2009, Enantia entered into the capital of Janus Developments along with two additional investors: the pharmaceutical group Ferrer Internacional and the financial institution Caixa Manresa. Following Enantia's strategy to be closer to the emerging biotech sector, we decided to tighten relations with the recently founded start-up Janus Developments by entering into its capital. More detailed information can be found in the article appeared in Diario Expansión on January 20^th, 2010.

(Jan 20th, 2010)

From February 16th to 19th Enantia will be exhibiting at InformEx USA 2010 in San Francisco. We kindly invite you to visit our booth (1440) and discuss how we can contribute to your projects.

(Jan 11th, 2010)